TIMP1 and breast carcinoma: Breast cancer cells overexpressing TIMP-1, a well-known inhibitor of matrix metalloproteinase, exhibit a reduced sensitivity to the chemotherapeutic drugs paclitaxel and epirubicin through the activation of transcription factor NF-κB [39].